11.17.14
New clinical evidence indicates that the Obeminale Program utilizing Stablor —a novel food product that targets the underlying causes of abdominal obesity— contributed to a reduction in the cardiometabolic risk factors associated with obesity co-morbidities. Such risk factors, including high triglycerides, hyperglycemia and low HDL cholesterol, were mitigated with the patented medical food, developed by LNC (Laboratoires Nutrition et Cardiometabolisme), Bordeaux, France, a research and development company specializing in the field of chronic metabolic diseases.
Consolidated results from two clinical studies and product usage in real clinical practice demonstrated that in less than six months Stablor contributed to 18% fat loss, mostly in the waist area; 9% weight loss; a 9.5% decrease in waist circumference; at least 5% weight loss for 67% of patients; a high level of safety; and high patient compliance (a lower than 10% drop-out rate in clinical studies).
Stablor is composed of amino acids and micronutrients in specific proportions, and has been specifically engineered to decrease adipocyte dysfunction and adipose tissue inflammation. Additional clinical results have confirmed a significant decrease in inflammation (CRPus -11%) and a positive impact on insulin-resistance (HOMA IR -24%).
According to a recent report from the Journal of the American Medical Association (JAMA), the number of people with abdominal obesity (visceral fat) increased from 46.4% of the U.S. population in 1999-2000, to 54.2% in 2011-2012.
Stablor is now ready for market and can be prescribed to any individual with abdominal obesity and co-morbidities. It has already been prescribed to 5,000 individuals. LNC claimed that Stablor has the potential to strengthen the portfolio of any major business with a cardiometabolic focus. In addition, the company said a rapid launch in key markets would target up to 700 million people. “We welcome enquiries from potential partners. This can accelerate the commercialization of Stablor, making it available to a large number of users” said Jean-Luc Treillou, CEO at LNC.
LNC’s approach to the effective management of metabolic dysfunction also includes a patient-centric and behavioral approach called the Chronic Patient Initiative (CPI), a patient support program. Abdominally obese people have multiple health challenges (nutritional imbalances, lifestyle factors, etc.), and therefore LNC believes it is critical to address these issues simultaneously with a holistic approach to achieve lasting, long-term success.
The final results of the Obeminale program, to be published in early 2015, will include microbiota and adipose tissue details.
“We are convinced that LNC’s approach offers an effective patient management program in the field of cardiometabolic diseases,” said Claude Vincent, president at LNC. "Stablor is our lead product. However, as an R&D company we also have four additional programs under development: medical foods targeting metabolic disorders related to subfertility, bariatric surgery, pre-diabetes and Non-Alcoholic SteatoHepatitis (NASH) — with successive market launches planned over the next four years.”
Consolidated results from two clinical studies and product usage in real clinical practice demonstrated that in less than six months Stablor contributed to 18% fat loss, mostly in the waist area; 9% weight loss; a 9.5% decrease in waist circumference; at least 5% weight loss for 67% of patients; a high level of safety; and high patient compliance (a lower than 10% drop-out rate in clinical studies).
Stablor is composed of amino acids and micronutrients in specific proportions, and has been specifically engineered to decrease adipocyte dysfunction and adipose tissue inflammation. Additional clinical results have confirmed a significant decrease in inflammation (CRPus -11%) and a positive impact on insulin-resistance (HOMA IR -24%).
According to a recent report from the Journal of the American Medical Association (JAMA), the number of people with abdominal obesity (visceral fat) increased from 46.4% of the U.S. population in 1999-2000, to 54.2% in 2011-2012.
Stablor is now ready for market and can be prescribed to any individual with abdominal obesity and co-morbidities. It has already been prescribed to 5,000 individuals. LNC claimed that Stablor has the potential to strengthen the portfolio of any major business with a cardiometabolic focus. In addition, the company said a rapid launch in key markets would target up to 700 million people. “We welcome enquiries from potential partners. This can accelerate the commercialization of Stablor, making it available to a large number of users” said Jean-Luc Treillou, CEO at LNC.
LNC’s approach to the effective management of metabolic dysfunction also includes a patient-centric and behavioral approach called the Chronic Patient Initiative (CPI), a patient support program. Abdominally obese people have multiple health challenges (nutritional imbalances, lifestyle factors, etc.), and therefore LNC believes it is critical to address these issues simultaneously with a holistic approach to achieve lasting, long-term success.
The final results of the Obeminale program, to be published in early 2015, will include microbiota and adipose tissue details.
“We are convinced that LNC’s approach offers an effective patient management program in the field of cardiometabolic diseases,” said Claude Vincent, president at LNC. "Stablor is our lead product. However, as an R&D company we also have four additional programs under development: medical foods targeting metabolic disorders related to subfertility, bariatric surgery, pre-diabetes and Non-Alcoholic SteatoHepatitis (NASH) — with successive market launches planned over the next four years.”
